Recent progress in the development of selective S1P1 receptor agonists for the treatment of inflammatory and autoimmune disorders

Bibliography

• English D, Welch Z, Kovala AT, et al. Sphingosine-1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000;14:2255-65
   PubMed Web of Science ®Google Scholar
• Prieschl EE, Csonga R, Novotny V, et al. The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after Fc epsilon receptor I triggering. J Exp Med 1999;190:1-8
   PubMed Web of Science ®Google Scholar
• Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine-1-phosphate in blood. FASEB J 2007;21:1202-9
   PubMed Web of Science ®Google Scholar
• Ancellin N, Colmont C, Su J, et al. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine-1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002;277:6667-75
   PubMed Web of Science ®Google Scholar
• Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of pshingosine-1-phosphate. Science 2007;316:295-8
   PubMed Web of Science ®Google Scholar
• Rosen H, Goetzl EJ. Sphingosine-1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005;5:560-70
   PubMed Web of Science ®Google Scholar
• Le Stunff H, Peterson C, Liu H, et al. Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta 2002;1582:8-17
   PubMed Web of Science ®Google Scholar
• Brinkmann V. Sphingosine-1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115:84-105
   PubMed Web of Science ®Google Scholar
• Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1 phosphate receptors: implication for the treatment of FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008;117:77-93
   PubMed Web of Science ®Google Scholar
• Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine-1 phosphate receptor. Nat Immunol 2007;8:1337-44
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
   PubMed Web of Science ®Google Scholar
• Adachi K, Kohara T, Nakao N, et al. Design, synthesis and structure-activity relationships of 2-substituted 2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995;5(8):853-6
   Web of Science ®Google Scholar
• Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine-1-phosphate G protein coupled receptors. FASEB J 2004;18(3):551-3
   PubMed Web of Science ®Google Scholar
• Kabashima K, Haynes NM, Xu Y, et al. Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 2006;203(12):2683-90
   PubMed Web of Science ®Google Scholar
• Idzko M, Hammad H, van Nimwegen M, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006;116(11):2935-44
   PubMed Web of Science ®Google Scholar
• Brown BA, Kantesaria PP, Mcdevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 2008;41(10):1660-8
   Google Scholar
• Yoshitomi Pharmaceuticals Industries Ltd, Taito Co. Ltd. 2-Amino-1,3-propanediol compound and immunosuppressant. WO9408943; 1994
   Google Scholar
• Novartis AG. 2-Amino-propanol derivatives. WO02076995; 2002
   Google Scholar
• Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents. WO0218395; 2002
   Google Scholar
• Novartis Pharma GMBH, Mitsubishi Pharma Co. Organic compounds. WO04089341; 2004
   Google Scholar
• Welfide Corp. Medicinal compositions for preventing or treating viral myocarditis. WO0101978; 2001
   Google Scholar
• Novartis AG. Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function. WO02067915; 2002
   Google Scholar
• Novartis AG. Treatment or prophylaxis of insulin-producing cell graft rejection. WO02100148; 2002
   Google Scholar
• Novartis AG. Macrolides containing pharmaceutical compositions. WO03035068; 2003
   Google Scholar
• Novartis AG. Sphingosine-1-phosphate receptor agonists in the treatment of demylinating disorders. WO04028521; 2004
   Google Scholar
• Novartis AG. Amino-propanol derivatives as sphingosine-1-phosphate receptor modulators. WO04096757; 2004
   Google Scholar
• Novartis AG. Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator. WO04110979; 2004
   Google Scholar
• Novartis AG. Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator. WO04096752; 2004
   Google Scholar
• Novartis AG. Aminopropanol derivatives. WO05021503; 2005
   Google Scholar
• Novartis AG. Amino acid derivatives. WO05085179; 2005
   Google Scholar
• Irm Llc. Immunosuppressant compounds and compositions. WO04103306; 2004
   Google Scholar
• Irm Llc. Immunosuppressant compounds and compositions. WO05082841; 2005
   Google Scholar
• Irm Llc. Novel bicyclic compounds and compositions. WO04071442; 2004
   Google Scholar
• Irm Llc. Immunosuppressant compounds and compositions. WO04113330; 2004
   Google Scholar
• Irm Llc. Immunosuppressant compounds and compositions. WO04103309; 2004
   Google Scholar
• Irm Llc. Immunosuppressant compounds and compositions. WO05000833; 2005
   Google Scholar
• Irm Llc. Immunosuppressant compounds and compositions. WO05082089; 2005
   Google Scholar
• Irm Llc. Immunosuppressant compounds and compositions. WO07024922; 2007
   Google Scholar
• Novartis AG. Polycyclic oxadiazoles or isoxazoles and their use as S1P receptor ligands. WO06131336; 2006
   Google Scholar
• Novartis AG. 3,5-di(aryl or hetereoaryl) isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppressive and anti-inflammatory agents. WO07085451; 2007
   Google Scholar
• Novartis AG. Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties. WO08037476; 2008
   Google Scholar
• Novartis AG. Chromen-2-one derivatives. WO07115820; 2007
   Google Scholar
• Merck & Co., Inc. Aminoalkylphosphonates and related compounds as EDG receptor agonists. WO03073986; 2003
   Google Scholar
• Merck & Co., Inc. EDG receptor agonists. WO03062252; 2003
   Google Scholar
• Merck & Co., Inc. 1-((5-Aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as EDG receptor agonists. WO03105771; 2003
   Google Scholar
• Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists. WO05032465; 2005
   Google Scholar
• Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (EDG) receptor agonists. WO05058848; 2005
   Google Scholar
• Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists. WO06047195; 2006
   Google Scholar
• Merck & Co., Inc. 3-(2-Amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists. WO04103279; 2004
   Google Scholar
• Merck & Co., Inc. 1-(Amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles. WO04058149; 2004
   Google Scholar
• Actelion Pharmaceuticals Ltd. 4-Carbonyl substituted 1,1,2-trimethyl-1A,4,5,5A-tetrahydro-1H-4-aza-cyclopropanapentalene derivatives as agonists for the G-protein-coupled receptor S1P1/EDG1 and immunosuppressive agents. WO05123677; 2005
   Google Scholar
• Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents. WO06010379; 2006
   Google Scholar
• Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists. WO06100633; 2006
   Google Scholar
• Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists. WO06100635; 2006
   Google Scholar
• Actelion Pharmaceuticals Ltd. Hydrogenated benzo (c) thiophene derivatives as immunomodulators.WO06100631; 2006
   Google Scholar
• Actelion Pharmaceuticals Ltd. Novel thiophene derivatives. WO06137019; 2006
   Google Scholar
• Actelion Pharmaceuticals Ltd. Novel thiophene derivatives. WO07060626; 2007
   Google Scholar
• Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as S1P1/EDG1 receptor agonists. WO07080542; 2007
   Google Scholar
• Actelion Pharmaceuticals Ltd. Novel pyridine derivatives. WO07086001; 2007
   Google Scholar
• Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives as immunomodulating agents. WO08029371; 2008
   Google Scholar
• Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators. WO08035239; 2008
   Google Scholar
• Actelion Pharmaceuticals Ltd. Thiophene derivatives as S1P1/EDG1 receptor agonists. WO08029306; 2008
   Google Scholar
• Kyorin Pharmaceutical Co. Ltd. Diarylsulfide derivative, addition salt thereof, and immunosuppressant. US06960692; 2006
   Google Scholar
• Kyorin Pharmaceutical Co. Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators. US060160771; 2006
   Google Scholar
• Kyorin Pharmaceutical Co. Ltd. Aminocarboxylic acid derivative, addition salt thereof, and S1P receptor control agent. WO05044780; 2005
   Google Scholar
• Kyorin Pharmaceutical Co. Ltd. Dioxaphosphorinane derivatives, addition salts thereof and sphingosine-1-phosphate (S1P1, S1P4) receptor agonists. JP07169194; 2007
   Google Scholar
• Kyorin Pharmaceutical Co., Ltd. Oxaphosphinane derivatives, addition salts thereof and S1P receptor regulators. JP07169196; 2007
   Google Scholar
• Kyorin Pharmaceutical Co. Ltd. Aminosulfonic acid derivatives and addition salts thereof, and S1P receptor regulators. JP07001921; 2007
   Google Scholar
• Kyorin Pharmaceutical Co. Ltd. Aminophosphoric acid ester derivative and S1P receptor modulator containing the same as active ingredient. WO08018427; 2008
   Google Scholar
• Ono Pharmaceutical Co. Ltd. Aminocarboxylic acid derivative and medicinal use thereof. WO06064757; 2006
   Google Scholar
• Ono Pharmaceutical Co. Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof. WO05020882; 2005
   Google Scholar
• Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient. WO02092068; 2002
   Google Scholar
• Ono Pharmaceutical Co. Ltd. Sugar metabolism improvers. JP05162720; 2006
   Google Scholar
• Ono Pharmaceutical Co. Ltd. Compound having S1P receptor binding potency and use thereof. WO06001463; 2006
   Google Scholar
• University of Virginia. Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substituted by amino and phenyl groups. WO06088944; 2006
   Google Scholar
• University of Virginia. Method for treatment of neuropathic pain.WO07089715; 2007
   Google Scholar
• University of Virginia. Bicyclic sphingosine 1-phosphate analogs. WO07092638; 2007
   Google Scholar
• University of Virginia. Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as S1P receptor agonists. WO07098474; 2007
   Google Scholar
• University of Virginia. Agonists and antagonists of sphingosine-1-phosphate receptors. WO02064616; 2002
   Google Scholar
• University of Virginia. Orally available sphingosine 1-phosphate receptors agonists and antagonists. WO05041899; 2005
   Google Scholar
• University of Virginia. Compounds active in sphingosine 1-phosphate signaling. WO04010949; 2004
   Google Scholar
• Taisho Pharmaceutical Co. Ltd. Triazole Derivative. WO06013948; 2006
   Google Scholar
• Taisho Pharmaceutical Co. Ltd. Triazole Derivative. WO07089018; 2007
   Google Scholar
• Taisho Pharmaceutical Co. Ltd. Binding inhibitor of sphingosine-1-phosphate. WO07091570; 2007
   Google Scholar
• Epix Pharmaceutical. S1P receptor modulating compounds and use thereof. WO07109334; 2007
   Google Scholar
• Epix Pharmaceutical. S1P receptor modulating compounds. WO07109330; 2007
   Google Scholar
• Praecis Pharmaceuticals, Inc.: third quarter 2006 financial results. Available from: http://www.thefreelibrary.com/PRAECIS+PHARMACEUTICALS+ INCORPORATED+Reports+Third+ Quarter+2006…-a0154138939
   Google Scholar
• Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity. US060223866; 2007
   Google Scholar
• Praecis Pharmaceuticals, Inc. Chemical compounds. WO08024196; 2008
   Google Scholar
• Praecis Pharmaceuticals, Inc. Agonists of the sphingosine-1-phosphate receptor. WO08019090; 2008
   Google Scholar
• Praecis Pharmaceuticals, Inc. Chemical compounds. WO08016692; 2008
   Google Scholar
• Praecis Pharmaceuticals, Inc. Agonists of the sphingosine-1-phosphate receptor (SLP). WO08016674; 2008
   Google Scholar
• Sun Pharmaceutical Industries Ltd. Novel dicarboxylic acid derivatives. WO06043149; 2006
   Google Scholar
• Daiichi Sankyo Co. Ltd: corporate communications, session 2. Available from: http://www.daiichisankyo.com/4less/cgi-bin/cs4view_obj.php/ d_ir_public_n1_eng/67/060328-002e-irsub-v2.pdf
   Google Scholar
• Nakamura T, Youesu K, Mizuno Y, et al. Synthesis and SAR studies of a novel class of S1P1 receptor antagonists. Bioorg Med Chem 2007;15:3548-64
   PubMedGoogle Scholar
• Sankyo Co. Ltd. Amino alcohol compound. WO05079788; 2005
   Google Scholar
• Sankyo Co. Ltd. Cyclic amine derivative containing PPAR regulator. WO06137509; 2006
   Google Scholar
• Sankyo Co. Ltd. Heteroarylamide lower carboxylic acid derivative. WO07129745; 2007
   Google Scholar
• Sankyo Co. Ltd. Novel amidopropionic acid derivative and pharmaceutical product containing same. WO07091396; 2007
   Google Scholar
• Sankyo Co. Ltd. Bicyclic aryl derivative. WO07129473; 2007
   Google Scholar
• Pfizer, Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof. WO07132307; 2007
   Google Scholar
• Asahi Kasei Pharma Corp. Amine compound. WO08023783; 2008
   Google Scholar
• Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity. WO08030843; 2008
   Google Scholar
• Astellas Pharm, Inc. Hetero compound. WO07116866; 2007
   Google Scholar